Ching-Yao Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ching-Yao Tsai has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chi-Hsien Peng
School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan
1 shared publication - De-Kuang Hwang
School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan
1 shared publication - Feng Zhang
Evidence‑Based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China
1 shared publication - Ke-Hung Chien
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan
1 shared publication - Kuan-Hsuan Chen
Department of Pharmacy, Taipei Veterans General Hospital, Taipei City, Taiwan
1 shared publication - Min-Yen Hsu
Department of Ophthalmology, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan
1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Archives of Public Health
- Vol. 84 (1)
Prevalence of reproductive system diseases among Taiwanese prisoners: a population-based study on gender and age differences
- 20 August 2026
- Published by Springer Nature in Archives of Public Health
- Vol. 84 (1)
Open AccessPrevalence of reproductive system diseases among Taiwanese prisoners: a population-based study on gender and age differences
- Open Access
- 6 October 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (10) , 1414
Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion
Objectives: Retinal vein occlusions (RVO) are associated with systemic risk factors. However, the ocular occlusive events might also influence a patient’s systemic condition. This study tried to investigate serum biomarkers associated with oxidative stress, before and after intravitreal anti-vascular endothelial growth factor (aVEGF) therapy in patients with RVOs. Methods: Newly-onset RVO patients were categorized into two groups: comorbid with macular edema requiring aVEGF therapy (treatment group) and no edema (observation group). Age and sex-matched patients (who received cataract surgery) were included as the control group. Intravitreal ranibizumab with a pro-re-nata regimen were administered. Serum samples were collected prior to treatment, at 6 and 12 months after therapy/observation and were collected once before controls who received cataract surgery. mRNA expression of sirtuin-1, its downstream genes, anti-oxidative biomarkers, and proinflammatory cytokines were measured. Results: There were 32, 26, and 34 patients enrolled in the treatment, observation, and control groups, respectively. The expressions of sirtuin-1 and its downstream genes were significantly lower in patients with RVO compared with the control group. Sirtuin-1 gene expression increased after 1 year of aVEGF therapy in the treatment group but remained unchanged in the observation group. Biomarkers of oxidative stress and proinflammatory cytokines were reduced after 1 year of aVEGF therapy. These biomarkers remained with no changes in the observation group. Conclusions: Our study showed that the systemic oxidative stress increased in RVO patients. The aVEGF therapy could alter the gene expression of anti-oxidative proteins and reduce systemic oxidative stress in these patients.
- 6 October 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (10) , 1414
Open AccessChanges in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion
Objectives: Retinal vein occlusions (RVO) are associated with systemic risk factors. However, the ocular occlusive events might also influence a patient’s systemic condition. This study tried to investigate serum biomarkers associated with oxidative stress, before and after intravitreal anti-vascular endothelial growth factor (aVEGF) therapy in patients with RVOs. Methods: Newly-onset RVO patients were categorized into two groups: comorbid with macular edema requiring aVEGF therapy (treatment group) and no edema (observation group). Age and sex-matched patients (who received cataract surgery) were included as the control group. Intravitreal ranibizumab with a pro-re-nata regimen were administered. Serum samples were collected prior to treatment, at 6 and 12 months after therapy/observation and were collected once before controls who received cataract surgery. mRNA expression of sirtuin-1, its downstream genes, anti-oxidative biomarkers, and proinflammatory cytokines were measured. Results: There were 32, 26, and 34 patients enrolled in the treatment, observation, and control groups, respectively. The expressions of sirtuin-1 and its downstream genes were significantly lower in patients with RVO compared with the control group. Sirtuin-1 gene expression increased after 1 year of aVEGF therapy in the treatment group but remained unchanged in the observation group. Biomarkers of oxidative stress and proinflammatory cytokines were reduced after 1 year of aVEGF therapy. These biomarkers remained with no changes in the observation group. Conclusions: Our study showed that the systemic oxidative stress increased in RVO patients. The aVEGF therapy could alter the gene expression of anti-oxidative proteins and reduce systemic oxidative stress in these patients.